Cargando…
Initial dose reduction of enzalutamide does not decrease the incidence of adverse events in castration-resistant prostate cancer
BACKGROUND: There was no clear evidence whether the initial dose of enzalutamide affects the incidence of adverse events (AEs), and oncological outcome in patients with castration-resistant prostate cancer (CRPC). METHODS: The clinical charts of 233 patients with CRPC treated with enzalutamide were...
Autores principales: | Tsuzuki, Shunsuke, Nakanishi, Shotaro, Tamaki, Mitsuyoshi, Oshiro, Takuma, Miki, Jun, Yamada, Hiroki, Shimomura, Tatsuya, Kimura, Takahiro, Furuta, Nozomu, Saito, Seiichi, Egawa, Shin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8486121/ https://www.ncbi.nlm.nih.gov/pubmed/34597353 http://dx.doi.org/10.1371/journal.pone.0258160 |
Ejemplares similares
-
Three-month early change in prostate-specific antigen levels as a predictive marker for overall survival during hormonal therapy for metastatic hormone-sensitive prostate cancer
por: Nakanishi, Shotaro, et al.
Publicado: (2021) -
Risk Factors for Perioperative Hemodynamic Instability in Pheochromocytoma: A Systematic Review and Meta-Analysis
por: Urabe, Fumihiko, et al.
Publicado: (2021) -
Enzalutamide in patients with non-metastatic castration-resistant prostate cancer after combined androgen blockade for recurrence following radical treatment in Japan (Japanese research for patients with non-metastatic castration-resistant prostate cancer-enzalutamide: JCASTRE-zero)—a prospective single-arm interventional study
por: Sugimoto, Mikio, et al.
Publicado: (2022) -
Real-world use of enzalutamide in men with nonmetastatic castration-resistant prostate cancer in Japan
por: Yokomizo, Akira, et al.
Publicado: (2021) -
Correction to: Real-world use of enzalutamide in men with nonmetastatic castration-resistant prostate cancer in Japan
por: Yokomizo, Akira, et al.
Publicado: (2022)